Advice
Medicine discontinued
In February 2026, the Marketing Authorisation for sotrovimab (Xevudy®) was discontinued.
Medicine details
- Medicine name:
- sotrovimab (Xevudy)
- SMC ID:
- SMC2555
- Indication:
For the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Infections
- Submission type
- Collaboration
- Status
- Withdrawn
- Date advice published
- 29 March 2023
Additional notes
Medicine discontinued
In February 2026, the Marketing Authorisation for sotrovimab (Xevudy®) was discontinued.